About MSD

SPONSOR PROFILE: About MSD Merck Sharp and Dohme (MSD) is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, MSD discovers, develops, manufactures and markets vaccines and drugs to address unmet medical needs. MSD China was formed in 1994 in partnership with Hangzhou Huadong Medicine Group Co. Ltd. From the beginning, MSD China has been a socially responsible, innovative company contributing to improved health and economic growth. MSD China is committed to bringing its high quality medicines and vaccines to the Chinese people. To date, the company has launched four new vaccines as well as 15 innovative drugs to treat cardiovascular diseases, serious infections, respiratory and musculoskeletal conditions, urinary problems and neurological disorders. With more than 2200 highly skilled, motivated employees throughout the country, MSD China is committed to bringing its high quality medicines and vaccines to the Chinese people. To date, the company has launched four new vaccines as well as 15 innovative drugs to treat cardiovascular diseases, serious infections, respiratory and musculoskeletal conditions, urinary problems and neurological disorders. Through our research partnerships in China, we isolate and test the company’s best drug candidates against specific disease targets, and develop new biomarkers to contribute to the early detection and treatment of various forms of cancer. Our expert chemical and manufacturing engineers produce numerous medicines for the Chinese market in our state-of-the-art, 12,000m2, production facility in Hangzhou. Our sales and marketing team is made of some of China’s top business talent from leading universities. Human resources is one of MSD China’s greatest assets and its commitment to social causes is firmly anchored in its culture. In 1989, MSD transferred its innovative hepatitis B vaccine technology to China for $1; MSD built two high-tech manufacturing plants and trained Chinese scientists and engineers to produce the vaccine. As a result of this collaboration and the outstanding immunization program led by China’s Centers for Disease Control, hepatitis B infection rates declined from 10 percent of the population in 1989 to less than 1 percent today. MSD is also proud to participate in the first large-scale public-private partnership for HIV/AIDS prevention and control in China. In collaboration with China’s Ministry of Health, the partnership provides access to HIV education, training, testing, counseling, treatment and care through more than 1600 implementing organizations. MSD has committed USD $30 million to support this partnership and is dedicated to improving the lives of HIV/AIDS patients and their families in China.

About MSD

SPONSOR PROFILE:

About MSD

Become a Member of

Published In

December 2009

Related Research Resources

Why Do Some People Get Drunk Faster Than Others?

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Sex Differences in Neurological Research

New Frontiers in Vaccine Development

New Approaches for Decoding Cancer at the Single-Cell Level

Organoids as a Tool for Tissue Regeneration Research

Products

Product News

Artificial Inc. proof-of-concept data demonstrates platform capabilities with NVIDIA’s BioNeMo

Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators

Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

Accelerating Mycoplasma Testing for Targeted Therapy Development